Table 2.
Categories | Married (n) | Unmarried (n) | Unknown (n) | P‐value | |
---|---|---|---|---|---|
PD | |||||
Age at diagnosis (years) | 18–49 | 69 | 36 | 9 | 0.002 |
50–79 | 147 | 168 | 40 | ||
Race | White | 187 | 170 | 36 | 0.027 |
Black | 16 | 24 | 5 | ||
Other | 13 | 10 | 8 | ||
Laterality | Left | 109 | 113 | 15 | 0.004 |
Right | 107 | 86 | 33 | ||
Paired site | 0 | 5 | 1 | ||
Unknown | 0 | 0 | 0 | ||
Tumor size (cm) | <2 | 16 | 25 | 13 | <0.001 |
2.1–5 | 134 | 101 | 14 | ||
>5 | 0 | 5 | 4 | ||
Unknown | 66 | 73 | 18 | ||
Lymph node status | Negative | 84 | 69 | 5 | 0.001 |
Positive | 132 | 135 | 44 | ||
Grade | I | 6 | 5 | 0 | 0.523 |
II | 10 | 13 | 0 | ||
III | 22 | 14 | 5 | ||
IV | 2 | 1 | 0 | ||
Unknown | 176 | 171 | 44 | ||
AJCC stage | 0 | 49 | 28 | 6 | 0.177 |
I | 7 | 3 | 1 | ||
II | 0 | 1 | 1 | ||
III | 2 | 2 | 0 | ||
IV | 2 | 1 | 0 | ||
Unknown | 156 | 169 | 41 | ||
ER status | Negative | 33 | 34 | 7 | 0.249 |
Positive | 38 | 26 | 3 | ||
Borderline | 145 | 144 | 39 | ||
Unknown | 216 | 204 | 49 | ||
PR status | Negative | 48 | 39 | 8 | 0.641 |
Positive | 18 | 17 | 2 | ||
Borderline | 0 | 0 | 0 | ||
Unknown | 150 | 148 | 39 | ||
HER2 status | Negative | 4 | 3 | 0 | 0.695 |
Positive | 10 | 6 | 1 | ||
Borderline | 0 | 0 | 0 | ||
Unknown | 202 | 195 | 48 | ||
Radiation | No | 174 | 173 | 37 | <0.001 |
Yes | 36 | 27 | 4 | ||
Unknown | 6 | 4 | 8 | ||
PD‐IDC | |||||
Age at diagnosis (years) | 18–49 | 407 | 240 | 18 | <0.001 |
50–79 | 496 | 616 | 55 | ||
Race | White | 740 | 653 | 53 | <0.001 |
Black | 58 | 137 | 11 | ||
Other | 105 | 66 | 9 | ||
Laterality | Left | 481 | 443 | 35 | 0.715 |
Right | 422 | 412 | 38 | ||
Paired site | 0 | 1 | 0 | ||
Unknown | 0 | 0 | 0 | ||
Tumor size (cm) | <2 | 14 | 23 | 4 | 0.189 |
2.1–5 | 553 | 506 | 39 | ||
>5 | 14 | 14 | 0 | ||
Unknown | 322 | 313 | 30 | ||
Lymph node status | Negative | 407 | 366 | 34 | 0.562 |
Positive | 496 | 490 | 39 | ||
Grade | I | 43 | 67 | 3 | 0.169 |
II | 266 | 236 | 24 | ||
III | 498 | 469 | 36 | ||
IV | 25 | 18 | 1 | ||
Unknown | 71 | 66 | 9 | ||
AJCC stage | 0 | 1 | 3 | 0 | 0.411 |
I | 86 | 60 | 7 | ||
II | 45 | 58 | 3 | ||
III | 49 | 41 | 5 | ||
IV | 13 | 8 | 0 | ||
Unknown | 709 | 686 | 58 | ||
ER status | Negative | 397 | 347 | 25 | 0.01 |
Positive | 424 | 391 | 34 | ||
Borderline | 3 | 8 | 0 | ||
Unknown | 79 | 110 | 14 | ||
PR status | Negative | 492 | 456 | 35 | 0.006 |
Positive | 314 | 279 | 20 | ||
Borderline | 5 | 4 | 2 | ||
Unknown | 92 | 117 | 16 | ||
HER2 status | Negative | 56 | 63 | 4 | 0.025 |
Positive | 114 | 88 | 8 | ||
Borderline | 5 | 1 | 2 | ||
Unknown | 728 | 704 | 59 | ||
Radiation | No | 634 | 660 | 45 | <0.001 |
Yes | 244 | 174 | 17 | ||
Unknown | 16 | 22 | 11 | ||
Age at diagnosis (years) | 18–49 | 407 | 240 | 18 | <0.001 |
50–79 | 496 | 616 | 55 | ||
Race | White | 740 | 653 | 53 | <0.001 |
Black | 58 | 137 | 11 | ||
Other | 105 | 66 | 9 | ||
Laterality | Left | 481 | 443 | 35 | 0.715 |
Right | 422 | 412 | 38 | ||
Paired site | 0 | 1 | 0 | ||
Unknown | 0 | 0 | 0 | ||
Tumor size (cm) | <2 | 14 | 23 | 4 | 0.189 |
2.1–5 | 553 | 506 | 39 | ||
>5 | 14 | 14 | 0 | ||
Unknown | 322 | 313 | 30 | ||
Lymph node status | Negative | 407 | 366 | 34 | 0.562 |
Positive | 496 | 490 | 39 | ||
Grade | I | 43 | 67 | 3 | 0.169 |
II | 266 | 236 | 24 | ||
III | 498 | 469 | 36 | ||
IV | 25 | 18 | 1 | ||
Unknown | 71 | 66 | 9 | ||
AJCC stage | 0 | 1 | 3 | 0 | 0.411 |
I | 86 | 60 | 7 | ||
II | 45 | 58 | 3 | ||
III | 49 | 41 | 5 | ||
IV | 13 | 8 | 0 | ||
Unknown | 709 | 686 | 58 | ||
ER status | Negative | 397 | 347 | 25 | 0.01 |
Positive | 424 | 391 | 34 | ||
Borderline | 3 | 8 | 0 | ||
Unknown | 79 | 110 | 14 | ||
PR status | Negative | 492 | 456 | 35 | 0.006 |
Positive | 314 | 279 | 20 | ||
Borderline | 5 | 4 | 2 | ||
Unknown | 92 | 117 | 16 | ||
HER2 status | Negative | 56 | 63 | 4 | 0.025 |
Positive | 114 | 88 | 8 | ||
Borderline | 5 | 1 | 2 | ||
Unknown | 728 | 704 | 59 | ||
Radiation | No | 634 | 660 | 45 | <0.001 |
Yes | 244 | 174 | 17 | ||
Unknown | 16 | 22 | 11 |
AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, infiltrating duct carcinoma; PD‐IDC, Paget disease concomitant infiltrating duct carcinoma; PD‐DCIS, Paget disease concomitant intraductal carcinoma, unmarried group included divorced, separated, single (never married), and widowed.